Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 188

1.

Randomized Phase II Trial of Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: CAO/ARO/AIO-12.

Fokas E, Allgäuer M, Polat B, Klautke G, Grabenbauer GG, Fietkau R, Kuhnt T, Staib L, Brunner T, Grosu AL, Schmiegel W, Jacobasch L, Weitz J, Folprecht G, Schlenska-Lange A, Flentje M, Germer CT, Grützmann R, Schwarzbach M, Paolucci V, Bechstein WO, Friede T, Ghadimi M, Hofheinz RD, Rödel C; German Rectal Cancer Study Group.

J Clin Oncol. 2019 May 31:JCO1900308. doi: 10.1200/JCO.19.00308. [Epub ahead of print]

PMID:
31150315
2.

A conditional error function approach for adaptive enrichment designs with continuous endpoints.

Placzek M, Friede T.

Stat Med. 2019 May 7. doi: 10.1002/sim.8154. [Epub ahead of print]

PMID:
31066093
3.

Absolute quantification of donor-derived cell-free DNA as a marker of rejection and graft injury in kidney transplantation: Results from a prospective observational study.

Oellerich M, Shipkova M, Asendorf T, Walson PD, Schauerte V, Mettenmeyer N, Kabakchiev M, Hasche G, Gröne HJ, Friede T, Wieland E, Schwenger V, Schütz E, Beck J.

Am J Transplant. 2019 May 7. doi: 10.1111/ajt.15416. [Epub ahead of print]

PMID:
31062511
4.

ROCK-ALS: Protocol for a Randomized, Placebo-Controlled, Double-Blind Phase IIa Trial of Safety, Tolerability and Efficacy of the Rho Kinase (ROCK) Inhibitor Fasudil in Amyotrophic Lateral Sclerosis.

Lingor P, Weber M, Camu W, Friede T, Hilgers R, Leha A, Neuwirth C, Günther R, Benatar M, Kuzma-Kozakiewicz M, Bidner H, Blankenstein C, Frontini R, Ludolph A, Koch JC; ROCK-ALS Investigators.

Front Neurol. 2019 Mar 27;10:293. doi: 10.3389/fneur.2019.00293. eCollection 2019.

5.

Exercise training in patients with a left ventricular assist device (Ex-VAD): rationale and design of a multicentre, prospective, assessor-blinded, randomized, controlled trial.

Bobenko A, Schoenrath F, Knierim JH, Friede T, Verheyen N, Mehra MR, Haykowsky M, Herrmann-Lingen C, Duvinage A, Pieske-Kraigher E, Halle M, Falk V, Pieske B, Edelmann F.

Eur J Heart Fail. 2019 Mar 28. doi: 10.1002/ejhf.1431. [Epub ahead of print]

PMID:
30924265
6.

Dynamically borrowing strength from another study through shrinkage estimation.

Röver C, Friede T.

Stat Methods Med Res. 2019 Mar 1:962280219833079. doi: 10.1177/0962280219833079. [Epub ahead of print]

PMID:
30821201
7.

Blinded sample size reestimation in event-driven clinical trials: Methods and an application in multiple sclerosis.

Friede T, Pohlmann H, Schmidli H.

Pharm Stat. 2019 May;18(3):351-365. doi: 10.1002/pst.1927. Epub 2019 Jan 16.

PMID:
30652403
8.

Likelihood-based random-effects meta-analysis with few studies: empirical and simulation studies.

Seide SE, Röver C, Friede T.

BMC Med Res Methodol. 2019 Jan 11;19(1):16. doi: 10.1186/s12874-018-0618-3.

9.

Sample size re-estimation for clinical trials with longitudinal negative binomial counts including time trends.

Asendorf T, Henderson R, Schmidli H, Friede T.

Stat Med. 2019 Apr 30;38(9):1503-1528. doi: 10.1002/sim.8061. Epub 2018 Dec 21.

PMID:
30575061
10.

Data on differential multivariable risk prediction of appropriate shock vs. competing mortality.

Bergau L, Willems R, Sprenkeler DJ, Fischer TH, Flevari P, Hasenfuß G, Katsaras D, Kirova A, Lehnart SE, Lüthje L, Röver C, Seegers J, Sossalla S, Dunnink A, Sritharan R, Tuinenburg AE, Vandenberk B, Vos MA, Wijers SC, Friede T, Zabel M.

Data Brief. 2018 Nov 9;21:2110-2116. doi: 10.1016/j.dib.2018.11.025. eCollection 2018 Dec.

11.

Semi-parametric analysis of overdispersed count and metric data with varying follow-up times: Asymptotic theory and small sample approximations.

Konietschke F, Friede T, Pauly M.

Biom J. 2019 May;61(3):616-629. doi: 10.1002/bimj.201800027. Epub 2018 Dec 5.

PMID:
30515878
12.

Sample size calculation in multi-centre clinical trials.

Harden M, Friede T.

BMC Med Res Methodol. 2018 Nov 29;18(1):156. doi: 10.1186/s12874-018-0602-y.

13.

Prognostic significance of emergency department bypass in stable and unstable patients with ST-segment elevation myocardial infarction.

Scholz KH, Friede T, Meyer T, Jacobshagen C, Lengenfelder B, Jung J, Fleischmann C, Moehlis H, Olbrich HG, Ott R, Elsässer A, Schröder S, Thilo C, Raut W, Franke A, Maier LS, Maier SK.

Eur Heart J Acute Cardiovasc Care. 2018 Nov 27:2048872618813907. doi: 10.1177/2048872618813907. [Epub ahead of print]

PMID:
30477317
14.

Baseline predictors for progression 4 years after Parkinson's disease diagnosis in the De Novo Parkinson Cohort (DeNoPa).

Mollenhauer B, Zimmermann J, Sixel-Döring F, Focke NK, Wicke T, Ebentheuer J, Schaumburg M, Lang E, Friede T, Trenkwalder C; DeNoPa Study Group.

Mov Disord. 2019 Jan;34(1):67-77. doi: 10.1002/mds.27492. Epub 2018 Nov 23.

PMID:
30468694
15.

On estimands and the analysis of adverse events in the presence of varying follow-up times within the benefit assessment of therapies.

Unkel S, Amiri M, Benda N, Beyersmann J, Knoerzer D, Kupas K, Langer F, Leverkus F, Loos A, Ose C, Proctor T, Schmoor C, Schwenke C, Skipka G, Unnebrink K, Voss F, Friede T.

Pharm Stat. 2019 Mar;18(2):166-183. doi: 10.1002/pst.1915. Epub 2018 Nov 20.

PMID:
30458579
16.

Recent advances in methodology for clinical trials in small populations: the InSPiRe project.

Friede T, Posch M, Zohar S, Alberti C, Benda N, Comets E, Day S, Dmitrienko A, Graf A, Günhan BK, Hee SW, Lentz F, Madan J, Miller F, Ondra T, Pearce M, Röver C, Toumazi A, Unkel S, Ursino M, Wassmer G, Stallard N.

Orphanet J Rare Dis. 2018 Oct 25;13(1):186. doi: 10.1186/s13023-018-0919-y. Review.

17.

Blinded continuous monitoring in clinical trials with recurrent event endpoints.

Friede T, Häring DA, Schmidli H.

Pharm Stat. 2019 Jan;18(1):54-64. doi: 10.1002/pst.1907. Epub 2018 Oct 21.

PMID:
30345693
18.

Insights into permanent pacemaker implantation following TAVR in a real-world cohort.

Tichelbäcker T, Bergau L, Puls M, Friede T, Mütze T, Maier LS, Frey N, Hasenfuß G, Zabel M, Jacobshagen C, Sossalla S.

PLoS One. 2018 Oct 17;13(10):e0204503. doi: 10.1371/journal.pone.0204503. eCollection 2018.

19.

Model averaging for robust extrapolation in evidence synthesis.

Röver C, Wandel S, Friede T.

Stat Med. 2019 Feb 20;38(4):674-694. doi: 10.1002/sim.7991. Epub 2018 Oct 10.

PMID:
30302781
20.

Rationale and design of the EU-CERT-ICD prospective study: comparative effectiveness of prophylactic ICD implantation.

Zabel M, Sticherling C, Willems R, Lubinski A, Bauer A, Bergau L, Braunschweig F, Brugada J, Brusich S, Conen D, Cygankiewicz I, Flevari P, Taborsky M, Hansen J, Hasenfuß G, Hatala R, Huikuri HV, Iovev S, Kääb S, Kaliska G, Kasprzak JD, Lüthje L, Malik M, Novotny T, Pavlović N, Schmidt G, Shalganov T, Sritharan R, Schlögl S, Szavits Nossan J, Traykov V, Tuinenburg AE, Velchev V, Vos MA, Willich SN, Friede T, Svendsen JH, Merkely B; EU-CERT-ICD Study Investigators.

ESC Heart Fail. 2019 Feb;6(1):182-193. doi: 10.1002/ehf2.12367. Epub 2018 Oct 9.

21.

Symptomatology and symptomatic treatment in multiple sclerosis: Results from a nationwide MS registry.

Rommer PS, Eichstädt K, Ellenberger D, Flachenecker P, Friede T, Haas J, Kleinschnitz C, Pöhlau D, Rienhoff O, Stahmann A, Zettl UK.

Mult Scler. 2018 Sep 19:1352458518799580. doi: 10.1177/1352458518799580. [Epub ahead of print]

PMID:
30230952
22.
23.

Decreasing longitudinal use of glucocorticosteroids in multiple sclerosis.

Ellenberger D, Eichstädt K, Flachenecker P, Friede T, Haas J, Kleinschnitz C, Pöhlau D, Rienhoff O, Stahmann A, Zettl UK, Rommer PS.

Mult Scler Relat Disord. 2018 Oct;25:173-174. doi: 10.1016/j.msard.2018.07.040. Epub 2018 Jul 24. No abstract available.

PMID:
30096682
24.

Contribution to the discussion of "When should meta-analysis avoid making hidden normality assumptions?" A Bayesian perspective.

Röver C, Friede T.

Biom J. 2018 Nov;60(6):1068-1070. doi: 10.1002/bimj.201800179. Epub 2018 Aug 1. No abstract available.

PMID:
30069981
25.

Differential multivariable risk prediction of appropriate shock versus competing mortality - A prospective cohort study to estimate benefits from ICD therapy.

Bergau L, Willems R, Sprenkeler DJ, Fischer TH, Flevari P, Hasenfuß G, Katsaras D, Kirova A, Lehnart SE, Lüthje L, Röver C, Seegers J, Sossalla S, Dunnink A, Sritharan R, Tuinenburg AE, Vandenberk B, Vos MA, Wijers SC, Friede T, Zabel M.

Int J Cardiol. 2018 Dec 1;272:102-107. doi: 10.1016/j.ijcard.2018.06.103. Epub 2018 Jun 28.

26.

Reducing antibiotic use for uncomplicated urinary tract infection in general practice by treatment with uva-ursi (REGATTA) - a double-blind, randomized, controlled comparative effectiveness trial.

Afshar K, Fleischmann N, Schmiemann G, Bleidorn J, Hummers-Pradier E, Friede T, Wegscheider K, Moore M, Gágyor I.

BMC Complement Altern Med. 2018 Jul 3;18(1):203. doi: 10.1186/s12906-018-2266-x.

27.

Group sequential designs with robust semiparametric recurrent event models.

Mütze T, Glimm E, Schmidli H, Friede T.

Stat Methods Med Res. 2018 Jan 1:962280218780538. doi: 10.1177/0962280218780538. [Epub ahead of print]

PMID:
29890892
28.

Robustness of testing procedures for confirmatory subpopulation analyses based on a continuous biomarker.

Graf AC, Wassmer G, Friede T, Gera RG, Posch M.

Stat Methods Med Res. 2019 Jun;28(6):1879-1892. doi: 10.1177/0962280218777538. Epub 2018 Jun 11.

PMID:
29888651
29.

Group sequential designs for negative binomial outcomes.

Mütze T, Glimm E, Schmidli H, Friede T.

Stat Methods Med Res. 2018 Jan 1:962280218773115. doi: 10.1177/0962280218773115. [Epub ahead of print]

PMID:
29770729
30.

Randomised controlled trial of a self-guided online fatigue intervention in multiple sclerosis.

Pöttgen J, Moss-Morris R, Wendebourg JM, Feddersen L, Lau S, Köpke S, Meyer B, Friede T, Penner IK, Heesen C, Gold SM.

J Neurol Neurosurg Psychiatry. 2018 Sep;89(9):970-976. doi: 10.1136/jnnp-2017-317463. Epub 2018 Mar 16.

PMID:
29549193
31.

Methods for evidence synthesis in the case of very few studies.

Bender R, Friede T, Koch A, Kuss O, Schlattmann P, Schwarzer G, Skipka G.

Res Synth Methods. 2018 Sep;9(3):382-392. doi: 10.1002/jrsm.1297. Epub 2018 Apr 6.

32.

dfpk: An R-package for Bayesian dose-finding designs using pharmacokinetics (PK) for phase I clinical trials.

Toumazi A, Comets E, Alberti C, Friede T, Lentz F, Stallard N, Zohar S, Ursino M.

Comput Methods Programs Biomed. 2018 Apr;157:163-177. doi: 10.1016/j.cmpb.2018.01.023. Epub 2018 Jan 31.

33.

Impact of treatment delay on mortality in ST-segment elevation myocardial infarction (STEMI) patients presenting with and without haemodynamic instability: results from the German prospective, multicentre FITT-STEMI trial.

Scholz KH, Maier SKG, Maier LS, Lengenfelder B, Jacobshagen C, Jung J, Fleischmann C, Werner GS, Olbrich HG, Ott R, Mudra H, Seidl K, Schulze PC, Weiss C, Haimerl J, Friede T, Meyer T.

Eur Heart J. 2018 Apr 1;39(13):1065-1074. doi: 10.1093/eurheartj/ehy004.

34.

Differences in the Reponses to Apheresis Therapy of Patients With 3 Histopathologically Classified Immunopathological Patterns of Multiple Sclerosis.

Stork L, Ellenberger D, Beißbarth T, Friede T, Lucchinetti CF, Brück W, Metz I.

JAMA Neurol. 2018 Apr 1;75(4):428-435. doi: 10.1001/jamaneurol.2017.4842.

35.

Reclassifying Acute Respiratory Distress Syndrome.

Maiolo G, Collino F, Vasques F, Rapetti F, Tonetti T, Romitti F, Cressoni M, Chiumello D, Moerer O, Herrmann P, Friede T, Quintel M, Gattinoni L.

Am J Respir Crit Care Med. 2018 Jun 15;197(12):1586-1595. doi: 10.1164/rccm.201709-1804OC.

PMID:
29345967
36.

Clinical trials with nested subgroups: Analysis, sample size determination and internal pilot studies.

Placzek M, Friede T.

Stat Methods Med Res. 2018 Nov;27(11):3286-3303. doi: 10.1177/0962280217696116. Epub 2017 Mar 14.

PMID:
29298604
37.

Treatment of fatigue in amyotrophic lateral sclerosis/motor neuron disease.

Gibbons C, Pagnini F, Friede T, Young CA.

Cochrane Database Syst Rev. 2018 Jan 2;1:CD011005. doi: 10.1002/14651858.CD011005.pub2. Review.

38.

A standardised frankincense extract reduces disease activity in relapsing-remitting multiple sclerosis (the SABA phase IIa trial).

Stürner KH, Stellmann JP, Dörr J, Paul F, Friede T, Schammler S, Reinhardt S, Gellissen S, Weissflog G, Faizy TD, Werz O, Fleischer S, Vaas LAI, Herrmann F, Pless O, Martin R, Heesen C.

J Neurol Neurosurg Psychiatry. 2018 Apr;89(4):330-338. doi: 10.1136/jnnp-2017-317101. Epub 2017 Dec 16.

PMID:
29248894
39.

A design-by-treatment interaction model for network meta-analysis and meta-regression with integrated nested Laplace approximations.

Günhan BK, Friede T, Held L.

Res Synth Methods. 2018 Jun;9(2):179-194. doi: 10.1002/jrsm.1285. Epub 2018 Jan 16.

40.

Sample size re-estimation incorporating prior information on a nuisance parameter.

Mütze T, Schmidli H, Friede T.

Pharm Stat. 2018 Mar;17(2):126-143. doi: 10.1002/pst.1837. Epub 2017 Nov 27.

PMID:
29181869
41.

Echocardiographic Estimation of Mean Pulmonary Artery Pressure: A Comparison of Different Approaches to Assign the Likelihood of Pulmonary Hypertension.

Hellenkamp K, Unsöld B, Mushemi-Blake S, Shah AM, Friede T, Hasenfuß G, Seidler T.

J Am Soc Echocardiogr. 2018 Jan;31(1):89-98. doi: 10.1016/j.echo.2017.09.009. Epub 2017 Nov 23.

PMID:
29174340
42.

Predictors of mortality and ICD shock therapy in primary prophylactic ICD patients-A systematic review and meta-analysis.

Bergau L, Tichelbäcker T, Kessel B, Lüthje L, Fischer TH, Friede T, Zabel M.

PLoS One. 2017 Oct 17;12(10):e0186387. doi: 10.1371/journal.pone.0186387. eCollection 2017. Review.

43.

Sex differences in outcomes of primary prevention implantable cardioverter-defibrillator therapy: combined registry data from eleven European countries.

Sticherling C, Arendacka B, Svendsen JH, Wijers S, Friede T, Stockinger J, Dommasch M, Merkely B, Willems R, Lubinski A, Scharfe M, Braunschweig F, Svetlosak M, Zürn CS, Huikuri H, Flevari P, Lund-Andersen C, Schaer BA, Tuinenburg AE, Bergau L, Schmidt G, Szeplaki G, Vandenberk B, Kowalczyk E, Eick C, Juntilla J, Conen D, Zabel M; EU-CERT-ICD Investigators.

Europace. 2018 Jun 1;20(6):963-970. doi: 10.1093/europace/eux176. Erratum in: Europace. 2018 Jun 1;20(6):970.

44.

Patient-reported outcomes and survival in multiple sclerosis: A 10-year retrospective cohort study using the Multiple Sclerosis Impact Scale-29.

Raffel J, Wallace A, Gveric D, Reynolds R, Friede T, Nicholas R.

PLoS Med. 2017 Jul 10;14(7):e1002346. doi: 10.1371/journal.pmed.1002346. eCollection 2017 Jul.

45.

Modelling and sample size reestimation for longitudinal count data with incomplete follow up.

Asendorf T, Henderson R, Schmidli H, Friede T.

Stat Methods Med Res. 2019 Jan;28(1):117-133. doi: 10.1177/0962280217715664. Epub 2017 Jun 21.

PMID:
28633609
46.

Blinded sample size re-estimation in three-arm trials with 'gold standard' design.

Mütze T, Friede T.

Stat Med. 2017 Oct 15;36(23):3636-3653. doi: 10.1002/sim.7356. Epub 2017 Jun 12.

PMID:
28608469
47.

Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response.

Stellmann JP, Krumbholz M, Friede T, Gahlen A, Borisow N, Fischer K, Hellwig K, Pache F, Ruprecht K, Havla J, Kümpfel T, Aktas O, Hartung HP, Ringelstein M, Geis C, Kleinschnitz C, Berthele A, Hemmer B, Angstwurm K, Young KL, Schuster S, Stangel M, Lauda F, Tumani H, Mayer C, Zeltner L, Ziemann U, Linker RA, Schwab M, Marziniak M, Then Bergh F, Hofstadt-van Oy U, Neuhaus O, Zettl U, Faiss J, Wildemann B, Paul F, Jarius S, Trebst C, Kleiter I; NEMOS (Neuromyelitis Optica Study Group).

J Neurol Neurosurg Psychiatry. 2017 Aug;88(8):639-647. doi: 10.1136/jnnp-2017-315603. Epub 2017 Jun 1.

48.

Toward evidence-based diagnosis of myocarditis in children and adolescents: Rationale, design, and first baseline data of MYKKE, a multicenter registry and study platform.

Messroghli DR, Pickardt T, Fischer M, Opgen-Rhein B, Papakostas K, Böcker D, Jakob A, Khalil M, Mueller GC, Schmidt F, Kaestner M, Udink Ten Cate FEA, Wagner R, Ruf B, Kiski D, Wiegand G, Degener F, Bauer UMM, Friede T, Schubert S; MYKKE Consortium.

Am Heart J. 2017 May;187:133-144. doi: 10.1016/j.ahj.2017.02.027. Epub 2017 Feb 24.

PMID:
28454797
49.

Pharmacological Approaches to the Management of Secondary Progressive Multiple Sclerosis.

Nandoskar A, Raffel J, Scalfari AS, Friede T, Nicholas RS.

Drugs. 2017 May;77(8):885-910. doi: 10.1007/s40265-017-0726-0. Review.

PMID:
28429241
50.

Control conditions for randomised trials of behavioural interventions in psychiatry: a decision framework.

Gold SM, Enck P, Hasselmann H, Friede T, Hegerl U, Mohr DC, Otte C.

Lancet Psychiatry. 2017 Sep;4(9):725-732. doi: 10.1016/S2215-0366(17)30153-0. Epub 2017 Apr 7. Review.

PMID:
28396067

Supplemental Content

Loading ...
Support Center